Skip to content
PsilodexMedication × psilocybin
Your list 00
Methodology

How Psilodex is built.

What each record contains, what the codes mean, where the information comes from, and how it is kept current.

01 Scope
What it covers

A single administration session with natural psilocybin mushrooms in a state-regulated program: Colorado, Oregon and New Mexico. For each of 480 medications, supplements and substances: what is known about it with psilocybin, and what each state's rules say.

What it is not

Not medical advice, a screening decision, or clearance to participate. It does not rate a medication, recommend a change, or say whether someone can take part. Starting, stopping, or changing a medication is the prescriber's decision.

02 What a record containsEvery record, same order
01Name, brands, aliasesWhat people search for: generic, brand, common misspellings.
02ClinicalHow the clinical literature treats the combination: absolute, relative, or none listed.
03EvidenceThe kind of evidence behind the interaction text (codes below).
04InteractionWhat is known, in plain language, with a citation for every claim.
05State rulesFor each state: Named, Not named, Unsettled or Pending, with the rule number and what it says.
06ConditionsConditions a medication may imply that a state rule cares about. Confirmed with the person, never assumed.
07FlagsPharmacology properties, counted across a list on the report.
08Half-lifeFrom the FDA label where verified; otherwise “Not recorded”.
09SourcesEvery citation, numbered. Each record shows the date it was last reviewed.
03 Evidence codesA record can carry more than one
CodeMeaningUsed in
RCTControlled trial6 records
OLOpen-label trial5 records
CRCase reports or online surveys22 records
XPHuman data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text13 records
ThMechanism only (theoretical)188 records
PrStandard practice; no psilocybin-specific data277 records

Most records rest on mechanism or standard practice because few medications have been studied with psilocybin. A record's code describes the evidence; it is not a grade of safety.

04 Clinical levelsClinical data and state rules are separate facts
AbsoluteThe clinical literature treats the combination as contraindicated.11 records
RelativeSubstantial clinical concern; the literature treats it as a reason for caution or deferral.48 records
None listedNo clinical contraindication identified. With mechanism-only evidence, this reflects how little has been studied, not a finding of safety.421 records
05 State rule statuses
NamedA provision names this medication or its class.
Not namedNo provision names this medication or its class.
UnsettledWhether a provision applies to this medication is unsettled.
PendingRules are not final; no provision naming this medication has been found.

Rule text is checked against the official source; each state shows when it was last checked on the Sources page.

06 Pharmacology flags14 flags
F1Serotonergic
F2MAO inhibition
F3Blocks 5-HT2A (may blunt effects)
F4QT-prolonging
F5Raises blood pressure or heart rate
F6Lowers blood pressure or causes orthostasis
F7Lowers seizure threshold or carries seizure risk
F8Withdrawal or rebound if stopped abruptly
F9Anticholinergic
F10Sedating or CNS depressant
F11UGT inhibition (theoretical effect on psilocin levels)
F12Slows gastric emptying
F13Hypoglycemia risk
F14Dehydration or electrolyte risk

Each flag on a record is supported by a cited source. On the report, flags are counted across the whole list (for example, “Serotonergic · 2 / 4”) so overlapping properties are visible. A count is not a score.

07 Citation standard

Every record carries at least one public citation, and every flag is supported by a source that states it: an FDA label, a reference textbook page, a peer-reviewed paper or a government page. “No reported interaction” means the medication does not appear in the systematic reviews of psychedelic interactions, and is cited to those reviews. The data does not build if any record or flag lacks a source. All sources →

08 Review and updates
01Watch

Scheduled checks look for new FDA labels, state rule changes and new papers. Findings go to a review queue, never straight into the data.

02Review

Each change is checked against its source, with a second clinical reviewer for any change to a clinical level, evidence code or state rule.

03Build

The data is validated before release: every record needs a citation, every flag a source, no instruction-style wording.

04Release

A new dated version is published with a plain-language changelog. Earlier versions stay downloadable.

09 Limits
  • Most interaction evidence is thin: case reports, surveys, mechanism, or data from LSD rather than psilocybin.
  • Doses, timing, other medications and health conditions change how any combination plays out. A record cannot account for them.
  • A medication missing from the database is not a sign it is safe.
  • Rule summaries help find the right provision; the official rule text governs.
10 Report an error or a missing medication

Tell us what's wrong and, if you can, the source. Please don't include anything about yourself or anyone else's health. Accepted fixes appear in the changelog.

Report an errorSuggest a missing medicationOpens your email app · corrections@psilodex.org
Before you startTerms v2026-10-01

What Psilodex is, and isn't.

  1. 01It describes published evidence and state rules. It is not medical advice, a screening decision, or clearance to participate.
  2. 02Starting, stopping, or changing a medication is the prescriber's decision. Bring the report to them.
  3. 03Your list stays in this browser. Nothing you enter is sent anywhere.

In an emergency, call 911. Full terms and privacy.